| Description |
1 online resource (1 volume) |
| Contents |
Cover; Half Title; Title Page; Copyright Page; Dedication; Table of Contents; Foreword; Preface; Acknowledgments; Editors; Contributors; Section I : Nanotechnology-Based Approaches to Target Cancer; Chapter 1: Nanomedicines for Cancer; 1.1 Introduction; 1.2 Nanomedicines in Clinical Use and Under Clinical Trials; 1.2.1 Liposome-Based Nanomedicines; 1.2.2 Polymer-Based Nanomedicines; 1.2.3 Protein-Based Nanomedicines; 1.2.4 Micelles-Based Nanomedicines; 1.2.5 Nanotechnology-Based Miscellaneous Nanomedicines; 1.3 Targeting Mechanism of Nanomedicines; 1.3.1 Passive Targeting |
|
1.3.2 Active Targeting1.3.3 Stimuli-Responsive Nanomedicine; 1.4 Design Aspect of Nanomedicines; 1.4.1 Vascular Transport; 1.4.2 Transvascular Transport; 1.4.3 Interstitial Transport; 1.4.4 Intracellular Transport; 1.5 Enhancing Nanomedicine Translation through Clinically Relevant Models; 1.5.1 Standard Xenograft Models with Human Stroma Components; 1.5.2 Patient-Derived Tumor Xenograft (PDX) Model; 1.5.3 Humanized PDX Model; 1.5.4 Human Metastatic Site Model; 1.6 Challenges and Current Limitations; 1.7 Advantages and Disadvantages of Nanotechnology; 1.8 Conclusion; References |
|
Chapter 2: Effect of Nanocarrier Size/Surface on Molecular Targeting in Cancer2.1 Introduction; 2.2 Particle Size in Tumor Targeting; 2.2.1 Tumor Type and Pore Cutoff Size; 2.2.2 Circulation in Bloodstream; 2.2.3 Nanoparticle Trafficking and Tumor Internalization; 2.2.4 Cellular Uptake and Cell-Particle Interactions; 2.3 Particle Shape on Tumor Targeting; 2.3.1 Circulation in Bloodstream; 2.3.2 Nanoparticle Transportation and Tumor Internalization; 2.3.3 Cellular Uptake and Cell-Particle Interactions; 2.4 Influence of Nanocarrier Surface Properties on Tumor Targeting |
|
2.4.1 Circulation in Bloodstream2.4.2 Nanoparticle Transportation and Tumor Internalization; 2.4.3 Surface Functionalization with Targeting Tumors; 2.5 Conclusion; References; Chapter 3: Nanocarrier Systems for Anticancer Drug Delivery at the Subcellular Level; 3.1 Introduction; 3.2 Mitochondrial Targeted Drug Delivery; 3.2.1 Mitochondria and Cancer Therapy; 3.2.2 Mitochondrial Drug Delivery; 3.2.2.1 Mitochondriotropic Conjugated Nanocarriers; 3.2.2.2 Mitochondrial-Penetrating Peptide (MPP) Conjugated Nanocarriers; 3.2.2.3 Mitochondrial Targeting Signal (MTS) Conjugated Nanocarriers |
|
3.3 Nuclear Targeted Drug Delivery3.3.1 The Nucleus: Role in Cancer Treatment; 3.3.2 Nuclear Drug Delivery; 3.3.2.1 Nuclear Localization Signal (NLS) Conjugated Nanocarriers; 3.3.2.2 Other Approaches; 3.4 Lysosomal Targeted Drug Delivery; 3.4.1 Lysosomes; 3.4.2 Lysosomal Cell Death; 3.4.3 Lysosomal Drug Delivery; 3.4.3.1 Nanocarriers Containing Lysosomotropic Agents; 3.4.3.2 Nanocarriers Modified with Cathepsin-Specific Substrates; 3.4.3.3 Ceramide Containing Nanocarriers; 3.4.3.4 Metal Nanoparticles; 3.4.3.5 pH-Responsive Nanocarriers; 3.5 Endoplasmic Reticulum (ER) Targeted Drug Delivery |
| Summary |
The field of molecular medicine covers the medical interventions targeting molecular structures and mechanisms that are involved in disease progression. In cancer, several molecular mechanisms have been shown to impact its progression, aggressiveness and chemoresistance. Increasing evidence demonstrates the role of nanotechnology and outcome of molecular therapy. Several books have discussed molecular biology and mechanisms involved in cancer, but this text gives an account of molecular therapeutics in cancer relating to advancements of nanotechnology. It provides a description of the multidisciplinary field of molecular medicines and its targeted delivery to cancer using nanotechnology |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Deepak Chitkara is an Assistant Professor at the Department of Pharmacy, Birla Institute of Technology and Science (BITS)-Pilani, Vidya Vihar Campus, India. He obtained his Ph. D. in Pharmaceutical Sciences from the National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, India. He was an exchange research scholar at University of Tennessee Health Science Center, Memphis, TN for one year. After that he did his post-doctoral training at University of Nebraska Medical Center, Omaha, NE in the area of nanomedicines for pancreatic cancer. His research interests include the nano-based delivery systems for small molecules, miRNAs, and CRISPR/Cas genome editing tools. He has been working in the area of nanotechnology since 2007. Dr. Chitkara has developed and taught courses on "Advanced Drug delivery systems" and Advanced Pharmaceutical Technology to students of the Department of Pharmacy, BITS-Pilani. The mechanisms, designing, delivery, and therapeutic applications of small molecules, proteins and peptides and RNAi are extensively discussed in these courses. Anupama Mittal is an Assistant Professor at the Department of Pharmacy, Birla Institute of Technology and Science (BITS)-Pilani, India. She obtained her Ph. D. in Pharmaceutical Sciences from the National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, India, India and was a post-doctoral Research associate at the University of Nebraska Medical Center, Omaha, NE. She has been associated with several classroom courses entitled, Advanced Physical Pharmaceutics, Physical Pharmacy, Instrumental methods of analysis and Pharmaceutical Administration and management. She has also been teaching these courses to the industry professionals of different pharmaceutical industries including Lupin, Wockhardt, Sun Pharma etc. Her research interests include nanomedicines and exosomes for the treatment of cancer and diabetes and regenerative medicine. Her research group is also actively engaged in developing self-assembling drug conjugates for disease treatment. Her work has been published in several high impact journals of high repute and she has filed 2 product patents also. Ram I. Mahato is a Professor and Chairman of the Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE. He was a professor at the University of Tennessee Health Science Center, Research Assistant Professor at the University of Utah, Senior Scientist at GeneMedicine, Inc., and as a postdoctoral fellow at the University of Southern California in Los Angeles, Washington University in St. Louis, and Kyoto University, Japan. He received PhD in Drug Delivery from the University of Strathclyde and BS from China Pharmaceutical University. Dr. Mahato has published 140 papers, 17 book chapters, holds 2 US patents, and has edited/written eight books and ten journal issues (Total Google Citations= 9554 and h-Index =56). He was a Feature Editor of the Pharmaceutical Research (2006-2013) and Editorial Board Member of eight journals. He is a CRS and AAPS Fellow, Permanent Member of BTSS/NIH Study section, and ASGCT Scientific Advisor. He is applying sound principles in pharmaceutical sciences in the context of the latest advances in life and material sciences to solve challenging drug delivery problems in therapeutics |
|
Print version record |
| Subject |
Tumors.
|
|
Chemotherapy.
|
|
Neoplasms -- drug therapy
|
|
Molecular Targeted Therapy -- methods
|
|
Drug Delivery Systems
|
|
Nanostructures -- therapeutic use
|
|
Theranostic Nanomedicine -- methods
|
|
Molecular Medicine -- methods
|
|
Neoplasms
|
|
Drug Therapy
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
MEDICAL -- Pharmacology.
|
|
MEDICAL -- Pharmacy.
|
|
TECHNOLOGY -- Nanotechnology.
|
|
Chemotherapy
|
|
Tumors
|
| Form |
Electronic book
|
| Author |
Chitkara, Deepak, editor.
|
|
Mittal, Anupama, editor.
|
|
Mahato, Ram I., editor.
|
| ISBN |
9781315269214 |
|
131526921X |
|
9781351978378 |
|
1351978373 |
|
9781351978354 |
|
1351978357 |
|
9781351978361 |
|
1351978365 |
|
